Literature DB >> 11259087

Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma.

M H Kulke1, R D Odze, K S Thakore, G Thomas, H Wang, M Loda, C Eng.   

Abstract

PTEN is a putative tumour suppressor gene located on chromosome band 10q23. Mutations in PTEN have been identified in numerous human malignancies, including cancers of the brain, endometrium, ovary, and prostate. In this study, we screened 80 Barrett's oesophagus-associated adenocarcinomas (BOAd) for loss of heterozygosity (LOH) at 10q23, using the microsatellite markers D10S541, D10S219, and D10S551. Tumours demonstrating LOH were then screened for the presence or absence of PTEN mutations. LOH at one or more loci was identified in 17/80 (21%) cases. In none of these cases did we detect mutations in PTEN. The presence of LOH did not correlate with patient age, tumour stage, degree of differentiation, presence of perineural or vascular invasion, or overall survival. We conclude that LOH at chromosome 10q23 is uncommon in BOAd, is not associated with mutations in the PTEN tumour suppressor gene, and does not correlate with the clinical or pathologic features of these tumours. It is possible that PTEN is inactivated through other mechanisms in BOAd. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259087      PMCID: PMC2363812          DOI: 10.1054/bjoc.2000.1660

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  77 in total

1.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.

Authors:  M P Myers; J P Stolarov; C Eng; J Li; S I Wang; M H Wigler; R Parsons; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome.

Authors:  D J Marsh; P L Dahia; Z Zheng; D Liaw; R Parsons; R J Gorlin; C Eng
Journal:  Nat Genet       Date:  1997-08       Impact factor: 38.330

3.  PTEN1 is frequently mutated in primary endometrial carcinomas.

Authors:  D Kong; A Suzuki; T T Zou; A Sakurada; L W Kemp; S Wakatsuki; T Yokoyama; H Yamakawa; T Furukawa; M Sato; N Ohuchi; S Sato; J Yin; S Wang; J M Abraham; R F Souza; K N Smolinski; S J Meltzer; A Horii
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

4.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

Authors:  H Tashiro; M S Blazes; R Wu; K R Cho; S Bose; S I Wang; J Li; R Parsons; L H Ellenson
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

5.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

6.  Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers.

Authors:  F Muzeau; J F Fléjou; G Thomas; R Hamelin
Journal:  Int J Cancer       Date:  1997-07-03       Impact factor: 7.396

7.  Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.

Authors:  M V González; M L Artímez; L Rodrigo; C López-Larrea; M J Menéndez; V Alvarez; R Pérez; M F Fresno; M J Pérez; A Sampedro; E Coto
Journal:  J Clin Pathol       Date:  1997-03       Impact factor: 3.411

8.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

Authors:  P Guldberg; P thor Straten; A Birck; V Ahrenkiel; A F Kirkin; J Zeuthen
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

9.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.

Authors:  V Esposito; A Baldi; A De Luca; A M Groger; M Loda; G G Giordano; M Caputi; F Baldi; M Pagano; A Giordano
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

10.  Somatic mutations of PTEN in glioblastoma multiforme.

Authors:  S I Wang; J Puc; J Li; J N Bruce; P Cairns; D Sidransky; R Parsons
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

View more
  5 in total

1.  Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.

Authors:  Gregory A Watson; Xinglu Zhang; Michael T Stang; Ryan M Levy; Pierre E Queiroz de Oliveira; William E Gooding; James G Christensen; Steven J Hughes
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

2.  Assessment of mutational load in biopsy tissue provides additional information about genomic instability to histological classifications of Barrett's esophagus.

Authors:  Harshit S Khara; Sara A Jackson; Saraswathi Nair; Georgios Deftereos; Shweta Patel; Jan F Silverman; Eric Ellsworth; Cameron Sumner; Brendan Corcoran; Dennis M Smith; Sydney Finkelstein; Seth A Gross
Journal:  J Gastrointest Cancer       Date:  2014-06

3.  Computational methods reveal novel functionalities of PIWI-interacting RNAs in human papillomavirus-induced head and neck squamous cell carcinoma.

Authors:  Aswini R Krishnan; Yuanhao Qu; Pin Xue Li; Angela E Zou; Joseph A Califano; Jessica Wang-Rodriguez; Weg M Ongkeko
Journal:  Oncotarget       Date:  2017-12-19

4.  Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.

Authors:  Hidekazu Kuramochi; Kazumi Uchida; Jeffery H Peters; Daisuke Shimizu; Daniel Vallbohmer; Sylke Schneider; Kathleen D Danenberg; Peter V Danenberg
Journal:  BMC Cancer       Date:  2009-05-21       Impact factor: 4.430

5.  Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.

Authors:  Ian L P Beales; Olorunseun Ogunwobi; Ewen Cameron; Khalid El-Amin; Gabriel Mutungi; Mark Wilkinson
Journal:  BMC Cancer       Date:  2007-06-08       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.